Global Anthrax Vaccine Market Worth Over $22 Billion by 2034, Driven by Advanced Vaccine Developments and Rising Demand for Bioterrorism Defense
March 11, 2024 13:32 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Anthrax Vaccine Market by Vaccine Type, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
Déclaration d’actions et de droits de vote de la société Valneva - 29 février 2024
March 06, 2024 02:30 ET
|
VALNEVA
VALNEVA Déclaration d’actions et de droits de vote 29 février 2024__________________________________________________________________________________________ ...
VALNEVA Declaration of shares and voting rights - February 29, 2024
March 06, 2024 02:30 ET
|
VALNEVA
VALNEVA Declaration of shares and voting rights February 29, 2024__________________________________________________________________________________________ Company name:...
Valneva fera une présentation lors des conférences investisseurs TD Cowen et Van Lanschot Kempen
March 04, 2024 01:00 ET
|
VALNEVA
Saint-Herblain (France), 4 mars 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que des membres de son équipe dirigeante...
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
March 04, 2024 01:00 ET
|
VALNEVA
Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor...
Le Comité consultatif sur la vaccination aux États-Unis (ACIP) recommande l’utilisation d’IXCHIQ®, le vaccin à injection unique contre le chikungunya de Valneva
February 29, 2024 01:00 ET
|
VALNEVA
Le Comité consultatif sur la vaccination aux États-Unis (ACIP) recommande l’utilisation d’IXCHIQ®, le vaccin à injection unique contre le chikungunya de Valneva La recommandation pour l’utilisation...
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
February 29, 2024 01:00 ET
|
VALNEVA
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® Recommendation for use in travelers and laboratory workers follows U.S. Food and Drug...
Cholera Vaccines Market to Reach USD 167.3 Million by 2030, Fueled by a CAGR of 9.0% from 2030 | MarketDigits
February 27, 2024 08:15 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 27, 2024 (GLOBE NEWSWIRE) -- According to MarketDigits, the Cholera Vaccines Market was valued USD 91.50 Million in 2023 and projected to reach USD 167.3 Million by 2030, growing at a...
Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2023 et fournit des indications préliminaires pour l’exercice 2024
February 15, 2024 01:00 ET
|
VALNEVA
Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2023 et fournit des indications préliminaires pour l’exercice 2024 Chiffre d’affaires total de 153,7 millions d’euros dont 144,6...
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
February 15, 2024 01:00 ET
|
VALNEVA
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019)...